A nucleus-targeting peptide antagonist towards EZH2 displays therapeutic efficacy for lung cancer.
暂无分享,去创建一个
Chen Wang | Yanlian Yang | Lilusi Ma | Xiaocui Fang | Mengting Chen | Mei Jiang | Mingpeng Liu | Jingyi Liu | Mingpeng Liu
[1] Jintuan Huang,et al. NGFR Increases the Chemosensitivity of Colorectal Cancer Cells by Enhancing the Apoptotic and Autophagic Effects of 5-fluorouracil via the Activation of S100A9 , 2021, Frontiers in Oncology.
[2] Jian Liu,et al. Enhanced lymphatic delivery of nanomicelles encapsulating CXCR4-recognizing peptide and doxorubicin for the treatment of breast cancer. , 2020, International journal of pharmaceutics.
[3] Robin L. Jones,et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. , 2020, The Lancet. Oncology.
[4] J. Meng,et al. Synthetic CXCR4 Antagonistic Peptide Assembling with Nanoscaled Micelles Combat Acute Myeloid Leukemia. , 2020, Small.
[5] Sheridan M. Hoy. Tazemetostat: First Approval , 2020, Drugs.
[6] O. Elemento,et al. Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer. , 2020, Cell reports.
[7] N. Reguart,et al. In Search of the Long-Desired ‘Copernican Therapeutic Revolution’ in Small-Cell Lung Cancer , 2020, Drugs.
[8] Vrinda Gote,et al. Long-term delivery of protein and peptide therapeutics for cancer therapies , 2019, Expert opinion on drug delivery.
[9] A. Russo,et al. Therapeutic Approaches Targeting Nucleolus in Cancer , 2019, Cells.
[10] A. Mansfield,et al. Current Diagnosis and Management of Small-Cell Lung Cancer. , 2019, Mayo Clinic proceedings.
[11] Euan J. Rodger,et al. Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy. , 2019, Trends in immunology.
[12] J. Poyet,et al. Recent Advances in Cell Penetrating Peptide-Based Anticancer Therapies , 2019, Molecules.
[13] Qian Li,et al. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential , 2018, Biomarker Research.
[14] W. Béguelin,et al. Enhancer of zeste homolog 2 (EZH2) inhibitors , 2018, Leukemia & lymphoma.
[15] L. Tutar,et al. Tumor Targeting of Polymeric Nanoparticles Conjugated with Peptides, Saccharides, and Small Molecules for Anticancer Drugs. , 2018, Current pharmaceutical design.
[16] Roy S. Herbst,et al. The biology and management of non-small cell lung cancer , 2018, Nature.
[17] K. Uchimaru,et al. Targeting EZH2 in cancer therapy , 2017, Current opinion in oncology.
[18] Haiyan Xu,et al. Anti-tumor activity of nanomicelles encapsulating CXCR4 peptide antagonist E5 , 2017, PloS one.
[19] C. Rudin,et al. Unravelling the biology of SCLC: implications for therapy , 2017, Nature Reviews Clinical Oncology.
[20] C. Rudin,et al. Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. , 2017, Cancer cell.
[21] J. Meng,et al. A HSP60-targeting peptide for cell apoptosis imaging , 2016, Oncogenesis.
[22] C. Roberts,et al. Targeting EZH2 in cancer , 2016, Nature Medicine.
[23] B. Tang,et al. Peptide-Based Treatment: A Promising Cancer Therapy , 2015, Journal of immunology research.
[24] M. T. McCabe,et al. EZH2 as a potential target in cancer therapy. , 2014, Epigenomics.
[25] G. Liang,et al. Peptide-based nanostructures for cancer diagnosis and therapy. , 2014, Current medicinal chemistry.
[26] Bradley P. Coe,et al. EZH2 Promotes E2F-Driven SCLC Tumorigenesis through Modulation of Apoptosis and Cell-Cycle Regulation , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[27] Xiaoyan Xiao,et al. The expression and significance of the enhancer of zeste homolog 2 in lung adenocarcinoma. , 2012, Oncology reports.
[28] Jing Wang,et al. Delivery of drugs to cell membranes by encapsulation in PEG-PE micelles. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[29] E. Greer,et al. Histone methylation: a dynamic mark in health, disease and inheritance , 2012, Nature Reviews Genetics.
[30] Andrew J. Bannister,et al. Regulation of chromatin by histone modifications , 2011, Cell Research.
[31] D. Reinberg,et al. The Polycomb complex PRC2 and its mark in life , 2011, Nature.
[32] Robert Brown,et al. Ovarian Cancer Stem Cell–Like Side Populations Are Enriched Following Chemotherapy and Overexpress EZH2 , 2011, Molecular Cancer Therapeutics.
[33] Jing Wang,et al. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo , 2010, Cancer biology & therapy.
[34] Lisa Brannon-Peppas,et al. Active targeting schemes for nanoparticle systems in cancer therapeutics. , 2008, Advanced drug delivery reviews.
[35] Mark E. Davis,et al. Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.
[36] J. Karp,et al. Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .
[37] Steven F Dowdy,et al. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. , 2005, Advanced drug delivery reviews.
[38] E. Snyder,et al. Treatment of Terminal Peritoneal Carcinomatosis by a Transducible p53-Activating Peptide , 2004, PLoS biology.
[39] Vladimir P Torchilin,et al. Peptide and protein drug delivery to and into tumors: challenges and solutions. , 2003, Drug discovery today.
[40] H. Maeda,et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[41] S. Dowdy,et al. Transduced p16INK4a peptides inhibit hypophosphorylation of the retinoblastoma protein and cell cycle progression prior to activation of Cdk2 complexes in late G1. , 1999, Cancer research.
[42] G. Crabtree,et al. Affinity modulation of small-molecule ligands by borrowing endogenous protein surfaces. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[43] Natalie A. Lissy,et al. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration , 1998, Nature Medicine.
[44] Priscille Brodin,et al. A Truncated HIV-1 Tat Protein Basic Domain Rapidly Translocates through the Plasma Membrane and Accumulates in the Cell Nucleus* , 1997, The Journal of Biological Chemistry.
[45] M. Broggini,et al. p21WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth. , 1997, Cancer research.
[46] Carl O. Pabo,et al. Cellular uptake of the tat protein from human immunodeficiency virus , 1988, Cell.
[47] Maurice Green,et al. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein , 1988, Cell.
[48] M. Magzoub,et al. Cancer targeting peptides , 2019, Cellular and Molecular Life Sciences.
[49] A. Jemal,et al. Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.
[50] T. Hoffmann,et al. Peptide therapeutics: current status and future directions. , 2015, Drug discovery today.